The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

NCT02829502 on ClinicalTrials.gov · last registry update 2023-03-03

A small phase 2 — 30 participants, against a typical 110. Its estimated completion date, August 2023, has passed with no update to the record. Primary outcome, as filed: Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Christina Kruuse
Sponsor type: Other
Enrollment: 30
Started: 2016-08
Primary completion: 2023-08 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination.

Conditions studied

Ischemic Stroke

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.